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Abstract
Background: Increasing evidence highlights the important roles of tripartite motif containing 24 (TRIM24) in tumor
initiation and malignant progression in many tumors, including gastric cancer (GC). Although TRIM24 expression is
remarkably upregulated during GC carcinogenesis, the molecular mechanisms underlying TRIM24 dysregulation
remain unexplored.
Methods: In this study, miRNA target prediction tools were applied to explore miRNAs that potentially target
TRIM24. Western blot and quantitative reverse-transcriptase PCR (qRT-PCR) were performed to detected TRIM24
and miR-511 expression in GC tissues and cell lines. Dual-luciferase reporter assay was utilized to validate if TRIM24
is a direct target gene of miR-511. CCK-8 assay, cell colony formation assay, EdU incorporation assay and cell cycle
analysis were performed to determine whether miR-511-mediated regulation of TRIM24 could affect GC
progression.
Results: In our study, miR-511 was found to be downregulated in GC and an inverse correlation was observed
between TRIM24 and miR-511 expression in primary GC tissues and cell lines. Dual-luciferase reporter assay further
verified TRIM24 is a direct target of miR-511. Functional assays showed miR-511 overexpression inhibited cell
growth, colony formation ability and cell cycle progression. Conversely, inhibition of endogenous miR-511
promoted these phenotypes in GC cells. Moreover, reintroduction of TRIM24 rescued miR-511-induced inhibitory
effects on GC cells. Furthermore, miR-511 elicits tumor-suppressive effects through inactivating PI3K/AKT and Wnt/
β-catenin pathways by suppressing TRIM24.
Conclusions: Our results provide the new evidence supporting the tumor-suppressive role of miR-511 in GC by
suppressing TRIM24, suggesting that this novel miR-511/TRIM24 axis is critical in the control of gastric cancer
tumorigenesis.
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Background
Gastric cancer is the second leading cause of cancer-
related death globally [1], with a particularly high inci-
dence in China, accounting for nearly half of all new
cases worldwide [2]. Despite the decline in the inci-
dence and mortality of gastric cancer in the past de-
cades, the 5-year survival rate of gastric cancer patients
remains poor. Therefore, comprehensive elucidation of
the complex molecular mechanisms responsible for GC
development and progression are urgently needed.
TRIM24 (also known as TIF1α), belongs to the tripar-
tite motif protein family, was reported to be aberrantly
activated in a wide variety of cancers, including breast,
head and neck, hepatocellular carcinomas and lung
cancer [3–7]. Mounting evidence showed TRIM24 has
a key role in the modulation of the biological and
clinical behavior of tumor cells through interaction with
tumor-suppressive or oncogenic pathways [8–13]. For ex-
ample, TRIM24 binds and activates PIK3CA gene engaged
oncogenic PI3K/AKT signaling pathway in prostate cancer
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and glioma [14, 15]. Moreover, TRIM24 accelerates
tumor development and progression through promot-
ing phosphorylated p53 ubiquitination and degradation
[16–18]. In our previous study, we found TRIM24 was
upregulated in GC and its overexpression promoted tumor
malignant behaviors via activation of Wnt/β-catenin path-
way [19]. Despite the well-defined outcome of TRIM24
overexpression in cancers, the mechanism underlying
its upregulation in gastric cancer remains completely
unknown.
MicroRNAs (miRNAs), are small non-coding RNAs
that negatively regulate their target gene expression at
post-transcriptional levels by directly binding to the 3′
untranslated regions (3′UTRs) [20–22]. Numerous evi-
dence regarding miRNAs has unveiled a new dimension
to our understanding of tumorigenesis and its associ-
ated physiological processes, such as proliferation, cell
cycle, apoptosis and invasion [23–28]. Of note, a subset
of miRNAs has been linked to gastric cancer progression
due to their roles in the regulation of oncogenes or tumor
suppressor genes involved in GC tumorigenesis, such as
miR-362, miR-223, miR-506 and miR-144 [29–32]. Given
the important oncogenic role of TRIM24 in GC, we
decided to investigate whether TRIM24 expression is reg-
ulated by specific miRNAs, with the underlying hypothesis
that these regulatory miRNAs could also be critical in GC
pathogenesis.
In this study, miR-511, bioinformatically predicted as
a regulating miRNA of TRIM24, was found to be down-
regulated and inversely correlated with TRIM24 expres-
sion in GC tissues and cell lines. We further found that
upregulation of miR-511 inhibited GC proliferation,
and the inhibition of miR-511 had opposite effects. More-
over, our study demonstrated that TRIM24 was a func-
tional target gene of miR-511, and miR-511 inactivated
PI3K/AKT and Wnt/β-catenin pathways by suppressing
TRIM24. Taken together, our data unveiled the import-
ance of miR-511/TRIM24 axis in gastric carcinogenesis,
which may provide potential strategies for the treatment
of GC.
Methods
Patients and tissue samples
Primary gastric cancer tissues and their paired adjacent
normal tissues were obtained from 12 patients who re-
ceived surgery resection at the Department of Surgery of
the First Affiliated Hospital of Nanchang University.
Following resection fresh tissue samples were frozen in li-
quid nitrogen and stored at −80 °C. Clinicopathological
characteristics of patients were confirmed by two experi-
enced pathologists and summarized in Additional file 1:
Table S1. None of these patients received any chemother-
apy and radiotherapy before surgery.
Cell lines and cell culture
Five human gastric cancer cell lines (AGS, BGC823,
MGC803, HGC-27and SGC7901) and normal gastric
epithelial cell line GES-1 were obtained from Sun Yat-
Sen University Cancer Center. Cells were cultured in
RPMI-1640 medium (Hyclone, Logan, USA) with 10%
fetal bovine serum (FBS; Hyclone, Logan, USA), 100 U/
mL penicillin, and 100 μg/mL streptomycin (Invitrogen,
USA) in a humidified chamber at 37 °C and a 5% CO2
environment.
RNA extraction and quantitative reverse-transcriptase PCR
analysis
In this study, total RNA was extracted from frozen tissue
samples and cells by using TRIzol reagent (Invitrogen,
Carlsbad, USA) according to the manufacturer’s instruc-
tions. The complementary DNA (cDNA) was synthesized
using a reverse transcription kit (TransGen Biotech,
Beijing, China). RT-PCR was performed using the ABI
7500 real-time fast PCR system (Applied Biosystems,
Foster City, USA) and SYBR Green quantitative PCR
SuperMix (Invitrogen, Carlsbad, USA). The cycling condi-
tions were set as previously described [28]. Primers for
miR-511 and TRIM24 were purchased from Gene-
pharm Company (Shanghai, China). U6 or GAPDH
were used as internal controls and all data were ana-
lyzed using the 2-△△Ct method. Primer sequences are
presented in Table 1.
Western blot
Briefly, cells were lysed in lysis buffer consisting 50 mM
Tris/HCl (pH 7.5), 150 mM NaCl, 1 mM dithiothreitol
(DTT), 1 mM EDTA, 0.5% Nonidet P-40 (NP-40),
0.2 mM phenylmethylsulfonyl fluoride (PMSF), 10 μM
pepstatin A and 1 mM leupeptin. Equal amount of clear
cell lysates were separated by 10% SDS-PAGE and elec-
troblotted onto PVDF membrane (Bio-Rad Laboratories,
Hercules, USA). Membranes were blocked with 5% BSA
solution and then incubated with the following primary
antibodies overnight: TRIM24 (1:1000, Abcam, ab70560,
USA), phospho-AKT (p-AKT) (1:1000, Cell Signaling
Technology, #9297, USA), AKT (1:1000, Cell Signaling
Technology, #9272, USA), β-catenin (1:1000, Cell Signaling
Table 1 Primer sequences used in quantitative real-time PCR
Gene Primers
miR-511 forward: 5′- AGTGCTGGTGTCTTTTGCTCTG -3′
reverse: 5′- TATGGTTGTTCACGAGTCCTTCAC -3′
TRIM24 forward: 5′- CATATGCAGCAACAGCAACCG -3′
reverse: 5′- GAAAGCCATCTGTAGGGGGT -3′
U6 forward: 5′- AGAGCCTGTGGTGTCCG -3′
reverse: 5′- CATCTTCAAAGCACTTCCCT -3′
GAPDH forward: 5′-CATCACCATCTTCCAGGAGCG-3
reverse: 5′-TGACCTTGCCCACAGCCTTG-3′
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Technology, #9562, USA), cyclinD1 (1:1000, Cell Signaling
Technology, #2978, USA), c-Myc (1:1000, Cell Signaling
Technology, #5605) and β-actin (1:1500, Abcam, #6267,
USA). The following day, membranes were washed with
TBST and then incubated with horseradish peroxidase
(HRP)-conjugated corresponding second antibodies for 1 h
at room temperature. β-actin was used as an internal
control and protein bands were analyzed using Image
J software (Rawak Software, Germany).
Cell transfection
In this study, MGC803 and HGC-27 cells were transfected
with miR-511 mimics (sense:5′-GUGUCUUUUGCUCUG
CAGUCA-3′, antisense:5′-AGUGCAGAGCAAAAGAC
ACUU-3′) and negative control (NC, sense:5′-UUCUCC
GAACGUGUCACGUTT-3′, antisense:5′-ACGUGACAC
GUUCGGAGAATT-3′). Then SGC7901 cells were trans-
fected with miR-511 inhibitor (5′-UGACUGCAGAGCA
AAAGACAC-3′) and inhibitor negative control (inhibitor
NC, 5′-CAGUACUUUUGUGUAGUACAA-3′). TRIM24
expression vector without 3′-UTR (TRIM24-no UTR)
was constructed by inserting its CDS sequence into the
psiCHECK2 vector (Promega, USA). qRT-PCR analysis
and Western blot were performed to confirm the transfec-
tion efficiency.
CCK-8 assay
To assess the cell viability, the Cell Counting Kit-8
(CCK-8) (Dojindo Molecular Technologies, USA) was
used according to the manufacturer’s instructions. After
transfection for 24 h, cells were seeded in 96-well
plates. The cell viability was detected by adding WST-8
at a final concentration of 10%, and the absorbance of
these samples were measured at 450 nm on a Microplate
reader (Molecular Device, SpectraMax M5e, USA) every
24 h for 5 days. The data derived from triplicate samples
are presented as mean ± SD.
Colony formation assay
For the colony formation assay, MGC803, HGC-27 and
SGC7901 cells (500 per well) were seeded in a 60 mm-
dish at 24 h post-transfection and cultured in RPMI
1640 medium containing 10% fetal bovine serum for
10 days. Only colonies which reached more than 50 cells
were fixed with 10% formaldehyde for 15 min and dyed
with 8.0% crystal violet for 15 min. Each experiment was
repeated three times.
EdU incorporation assay
The effect of miR-511 on cell proliferation was also exam-
ined by EdU (5-Ethynyl-2′-deoxyuridine) incorporation
assay. Briefly, 24 h after transfection, indicated cells were
incubated with 50 μM EdU for 2 h at 37 °C according to
the manufacturer’s instructions (R11053.4, Apollo 567,
RiboBio, China). Cells were then washed with PBS for
three times, and fixed with 4% formaldehyde for 30 min
at room temperature. Next, 0.5% Triton X-100 was
applied for 10 min at room temperature to permeabilize
cells. After washing with PBS for three times, cells
were incubated with 1 × Apollo reaction cocktail for
30 min. DNA was stained with DAPI (4′,6-diamidino-
2-phenylindole) for 30 min and results were visualized
with a Zeiss confocal microscope (LSM 700, USA).
Flow cytometry analysis
Indicated cells were harvested by trypsinization, washed
with cold PBS and fixed in 70% cold ethanol in PBS.
Before staining, cells were spun down in a cooled cen-
trifuge and resuspended in cold PBS. Next, 100 μL of
RNase was added and cells were incubated at 37 °C for
30 min. Finally, cells were stained with PI (propidium
iodide, Thermo Fisher Scientific, P1304MP, USA) for
30 min at 4 °C and 5 × 104 cells were analyzed by flow
cytometry (Beckman-Coulter, Fullerton, CA, USA).
Dual-luciferase reporter assay
Prediction of miR-511 target genes was performed by two
independent miRNA databases: miRanda (http://www.
microrna.org/) and TargetScan (http://targetscan.org).
The full length 3′-UTR of the TRIM24 gene and a mutant
variant was amplified by PCR and cloned into the lucifer-
ase reporter psiCHECK2 vector (Promega, Madison,
USA). The wild-type plasmid (TRIM24-Wt-3′UTR) was
created containing the full-length 3′-UTR of TRIM24
with miR-511 complementary sequence. In addition, a
mutant-type plasmid (TRIM24-Mut-3′UTR) with a de-
generate 3′UTR was created by replacing AAAGACA
with UUUCUGU in the miR-511 complementary se-
quence. GC cells were seeded in 2 × 105 cells per well in
12-well plates and transiently co-transfected with reporter
plasmids (1 μg) and 100 nM of miR-511 mimics or miR-
511 inhibitor using Lipofectamin 2000 (Thermo Fisher
Scientific, #11668027, USA) for 48 h. The luciferase activ-
ity was measured using the Dual-luciferase Reporter Assay
Kit (Promega, Madison, USA, E1910) according to the
manufacturer’s protocols. Renilla luciferase was used for
normalization and all experiments were performed three
times.
Statistical analysis
Statistical analysis was performed using SPSS17.0
(Chicago, IL, USA). All data are presented as mean ± SD
and each experiment was repeated in triplicate. Student’s
t-test or variance (ANOVA) was employed to determine
statistical significance. A p value < 0.05 or less was con-
sidered statistically significant.
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Results
TRIM24 and miR-511 expression are inversely correlated
in GC tissues and cell lines
In this study, we examined TRIM24 protein expression
in 12 pairs of GC tissues and their corresponding adja-
cent non-cancerous gastric tissues. We found 10 out of
12 GC samples (83.3%) had increased TRIM24 expression
as compared with matched adjacent non-cancerous gastric
tissues (Fig. 1a, p < 0.05). To investigate the mechanism of
TRIM24 upregulation, bioinformatic tools were used to
identify the potential miRNAs targeting TRIM24. Al-
though many different miRNAs were predicted, three
candidates (miR-655, miR-374a and miR-511) attracted
our attention, because they were reported to be downreg-
ulated in several cancers, while their biological functions
in GC were unclear. Then we investigated the expression
of these candidate miRNAs in above-mentioned GC
tissues by qRT-PCR and found only miR-511 was mark-
edly downregulated in GC tissues, therefore, we focused
on miR-511 for further study.
As shown in Fig. 1b, miR-511 has potential target
sites in the 3′-UTR region of TRIM24 mRNA. qRT-
PCR results showed that miR-511 was consistently
downregulated in 12 matched paired of GC tissues
(Fig. 1c, p < 0.01), and was inversely correlated with
TRIM24 (Fig. 1d, r = −0.618, p < 0.01). Furthermore,
miR-511 and TRIM24 expression were also examined
in five human GC cell lines (AGS, BGC823, MGC803,
HGC-27, SGC7901) and normal gastric epithelial cell lines
GES-1, respectively. Additionally, the miR-511 expression
Fig. 1 TRIM24 and miR-511 expression are inversely correlated in gastric cancer tissues and cell lines. a TRIM24 protein expression in 12 pairs in
gastric cancer tissues (C) and corresponding adjacent non-cancerous gastric tissues (N) was detected by Western blot analysis. b The predicted
TRIM24 interaction site and its candidate targeted-miRNA, miR-511. c qRT-PCR analysis of miR-511 expression in gastric tumors and their corresponding
non-cancerous tissues, U6 was used as an internal control. d Correlation analysis of miR-511 expression and TRIM24 expression in clinical GC samples.
e qRT-PCR analysis of miR-511 expression in gastric cancer cell lines, U6 was used as an internal control. f TRIM24 expression in human gastric
cell lines we measured by qRT-PCR and Western blot. Data are presented as the mean ± SD. (*p < 0.05, **p < 0.01; n = 3)
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was much lower in MGC803 and HGC-27 cells, but rela-
tively higher in other three cancer cell lines, which was
inversely correlated with TRIM24 protein expression
(Fig. 1e and f). Thus, the inverse expression levels of miR-
511 and TRIM24 in GC tissues and cell lines indicate that
loss of miR-511 was related to the upregulation of
TRIM24.
TRIM24 is a direct target of miR-511
To determine whether TRIM24 is a direct target of miR-
511 in GC, we synthesized wild-type and mutant
TRIM24-3′UTR luciferase reporter constructs, in which
full length wild type or mutant TRIM24 3′UTR se-
quence was placed downstream of the luciferase reporter
gene (Fig. 2a). The miR-511 expression were detected by
qRT-PCR after transfection with miR-511 mimics or
inhibitor (Fig. 2b, p < 0.01). As shown in Fig. 2c, miR-
511 mimics markedly decreased the luciferase activity of
Wt-TRIM24-3′UTR plasmid in MGC803 and HGC-27
cells (p < 0.01), whereas miR-511 inhibitor upregulated
the luciferase activity in SGC7901 cells (p < 0.05).
Moreover, qRT-PCR results showed that overexpression
or knockdown of miR-511 did not affect degradation of
TRIM24 mRNA (Fig. 2d). However, western blot ana-
lysis showed that miR-511 upregulation significantly
suppressed TRIM24 protein expression in MGC803
and HGC-27 cells, and miR-511 downregulation in-
creased TRIM24 expression in SGC7901 cells (Fig. 2e
and Additional file 2: Figure S1), indicating that miR-
511 regulates TRIM24 through translational inhibition.
Fig. 2 Validation of TRIM24 as a direct target of miR-511. a Wild type (Wt) and Mutant type (Mut) TRIM24 3′UTR sequences were cloned into a
psi-CHECK reporter vector. b The miR-511 expression was detected by qRT-PCR at 48 h post-transfection, U6 was used as an internal control.
c The relative luciferase activity was detected by dual-luciferase reporter assay in indicated cell lines. d qRT-PCR analysis of TRIM24 mRNA
expression in indicated cell lines 24 h post-transfection. e TRIM24 protein expression was detected by Western blot in indicated cell lines
post-transfection. (*p < 0.05, **p < 0.01; n = 3)
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Collectively, these results strongly suggest that TRIM24
is a direct target of miR-511.
Ectopic expression of miR-511 inhibits proliferation of GC
cells
The above data promoted us to further explore the bio-
logical functions of miR-511 in GC cells. As presented
in Fig. 3a, the CCK8 assay showed that restoration of
miR-511 resulted in a markedly decreased cell viability
of MGC803 and HGC-27 cells. Consistently, a colony
formation assay revealed that the colony formation abil-
ity of MGC803 and HGC-27 cells was reduced in
response to miR-511 mimics (Fig. 3b, p<0.01). Moreover,
the level of DNA synthesis, detected with an EdU in-
corporation assay, was significantly suppressed in cells
transfected with miR-511 mimics, whereas the negative
control (NC) cells displayed relatively higher EdU in-
corporation rates (Fig. 3c, p < 0.01). Furthermore, flow
cytometry analysis revealed a significant increase in the
percentage of cells in G1/G0 phase and a decrease in the
percentage of cells in S phase in cells transfected with
miR-511 mimics (Fig. 3d, p < 0.01). Taken together, these
results clearly suggest that ectopic expression of miR-
511 inhibits cell proliferation of GC cells.
Fig. 3 Ectopic expression of miR-511 inhibits cell proliferation in GC cells. a The effect of miR-511 overexpression on cell viability was detected by
CCK-8 assay. b Representative micrographs (left) and quantification (right) of crystal violet-stained cell colonies. c Representative micrographs (left)
and quantification (right) of EdU incorporating-cells of indicated GC cells. d The effect of miR-511 upregulation on cell cycle progression of GC
cells was detected by flow cytometry analysis. (*p < 0.05, **p < 0.01; n = 3)
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Inhibition of miR-511 accelerates cell proliferation of GC
cells
We further assessed the effects of miR-511 inhibition on
GC cell proliferation in SGC7901 cells. As shown in
Fig. 4a and b, downregulation of miR-511 dramatically
enhanced the cell growth ability of SGC7901 cells com-
pared with that of cells transfected with negative control
(inhibitor NC), as analyzed by CCK8 and colony forma-
tion assays. In addition, the level of DNA synthesis was
significantly elevated in cells transfected with miR-511
inhibitor, whereas the control cells displayed relatively
lower EdU incorporation rates (Fig. 4c, p < 0.01). More-
over, cell cycle analysis revealed that transfection of
miR-511 inhibitor drastically increased the percentage of
cells in S peak while decreased percentages of cells in
G1/G0 peak (Fig. 4d, p < 0.05). Collectively, these data
indicate that downregulation of endogenous miR-511
expression accelerates cell proliferation of GC cells.
Overexpression of TRIM24 partially attenuates miR-511-
induced effects on GC cell proliferation
To ascertain whether the proliferation-inhibitory role of
miR-511 in GC cells was attributable to reduced TRIM24
expression, we carried out a series of rescue experiments
in MGC803 and HGC-27 cells. A TRIM24 overexpression
construct was synthesized to contain only the coding
sequences of TRIM24 without its 3′-UTR (TRIM24-no
UTR), yielding an mRNA that is resistant to miR-511-
mediated inhibition of translation. Then, miR-511 mimics,
with or without TRIM24-no UTR construct, were co-
transfected into MGC803 and HGC-27 cells. As illus-
trated in Fig. 5a, the resulting constitutive expression of
TRIM24 partially ameliorated the inhibition of TRIM24
protein expression mediated by miR-511. Furthermore,
CCK8, colony formation and Edu incorporation assays, as
well as cell cycle analysis, demonstrated that the restor-
ation of TRIM24 partially rescued miR-511-mediated
Fig. 4 Inhibition of miR-511 promotes cell proliferation in GC cells. a At indicated time points, the cell growth rate was evaulated by CCK-8 assay. b
Colony formation analysis of GC cells after indicated transfection. c Representative micrographs (left) and quantification (right) of EdU incorporating-
cells of after transfection with miR-511 inhibitor or inhibitor negative control (inhibitor NC). d The effect of miR-511 inhibition on the cell cycle progres-
sion of GC cells was determined by flow cytometry analysis. (*p < 0.05, **p < 0.01; n = 3)
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inhibitory effects on GC cell proliferation (Fig. 5b–e).
Taken together, these results further demonstrate that
TRIM24 is a main functional mediator of miR-511.
MiR-511 inactivates PI3K/AKT and Wnt/β-catenin signaling
pathways via suppressing TRIM24 in GC cells
TRIM24 was reported to exert its oncogenic activities in
many cancers through regulating PI3K/AKT pathways.
And our previous study demonstrated that TRIM24 was
a positive regulator of Wnt/β-catenin pathway. Thus,
we deduced that miR-511 might inhibit cell prolifera-
tion through inactivation of PI3K/AKT and Wnt/β-ca-
tenin pathways. As shown in Fig. 6a and b, miR-511
upregulation decreased, while miR-511 downregulation
increased the expression of p-AKT, β-catenin, cyclinD1
and c-Myc. However, the total levels of AKT in all groups
were not significantly changed. Another key question was
whether miR-511 repressed these two pathways in a
TRIM24-dependent manner. To investigate this hypoth-
esis, we overexpressed miR-511 together with a construct
Fig. 5 Overexpression of TRIM24 partially rescues miR-511-induced effects on GC cell proliferation. a Western blot analysis of TRIM24 protein
expression after transfection of MGC803 and HGC-27 cells with miR-511 mimics or miR-511 mimics and TRIM24-no UTR (TRIM24 without its
3′-UTR, shown as TRIM24). b At the indicated time points post-transfection, the cell growth rate was evaluated using the CCK8 assay. c Colony
formation assay analysis of GC cells after indicated treatments. d Representative micrographs (left) and quantification (right) of EdU incorporating-cells
after transfection with miR-511 mimics, or miR-511 mimics and TRIM24-no UTR. e The cell cycle distribution was detected by flow cytometric analysis
at 48 h post-transfection. (*p < 0.05, **p < 0.01; n = 3)
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expressing TRIM24 without 3′-UTR (TRIM24-no UTR)
in MGC803 and HGC-27 cells. Strikingly, we found that
overexpression of TRIM24 markedly but not completely
rescued the miR-511-mediated inhibition on PI3K/AKT
and Wnt/β-catenin pathways. Overall, these results indi-
cate that miR-511 suppresses the activity of PI3K/AKT
and Wnt/β-catenin pathways via TRIM24.
Discussion
TRIM24, as a founding member of TRIM family, has
been identified as being involved in physiologic and
pathological processes, including cell growth, apoptosis,
invasion and cancer development. Recent studies shed
important insights into the expression and function of
TRIM24 in carcinogenesis [33, 34]. Others and our
previous study showed that TRIM24 expression was ab-
normally upregulated in GC as compared with adjacent
gastric tissues, indicating the potential role of TRIM24
in GC progression. To date, few studies have investigated
the mechanism underlying TRIM24 overexpression in
GC. In this study, we identify miR-511 as a negative regu-
lator of TRIM24 in GC tumorigenesis.
MiRNAs are important non-coding RNAs, frequently
expressed aberrantly in tumorigenesis. Numerous evi-
dence has defined a role for miRNAs in modulation of the
process of GC proliferation, apoptosis, metastasis and
multidrug resistance. miR-511 has been reported to be
negatively regulated in different cancer types, including
lung cancer, hepatocellular carcinoma and ovarian cancer
[35–37]. It has also been found to act as a cancer-
suppressive miRNA by targeting important oncogenes,
such as PIK3R3, TRIB2 and Bax [37–39]. However, some
researchers found that miR-511 served as a onco-miR in
other cancers, such as HCV-associated diffuse large B-cell
lymphoma as well as in human blood monocyte-derived
dendritic cells and macrophages [40, 41]. Based on these
reports, it seems that miR-511 displays contrasting roles
in different tumor types, implying that the cancer type
determines the role of miR-511 as an oncogene or tumor
suppressor gene. However, few studies have paid attention
to the role of miR-511 in GC. In our study, miR-511 was
computationally predicted as a regulatory miRNA of
TRIM24. And we further clarified that miR-511 is signifi-
cantly downregulated in gastric cancer tissues when
compared to corresponding non-cancerous gastric tissues.
Moreover, the expression patterns of TRIM24 were
inversely correlated with those of miR-511 in GC clinical
samples and cell lines. Furthermore, TRIM24 was vali-
dated as a direct target gene of miR-511 by luciferase
reporter assay and Western blot. These data further
Fig. 6 MiR-511 inactivates PI3K/AKT and Wnt/β-catenin signaling pathways via suppressing TRIM24 in GC cells. a Western blot analysis of PI3K/
AKT and Wnt/β-catenin pathways target genes after transfection in MGC803 and HGC-27 cells with miR-511 mimics or negative control (NC).
b Western blot analysis of PI3K/AKT and Wnt/β-catenin pathways target genes after transfection with miR-511inhibitor or inhibitor negative
control in SGC7901 cells (inhibitor NC). c Western blot analysis of PI3K/AKT and Wnt/β-catenin pathways target genes after transfected with
miR-511 or co-transfection with miR-511 mimics and TRIM24-no UTR. β-actin was used as an internal control. (*p < 0.05, **p < 0.01; n = 3)
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underscore a potentially important role of miR-511
downregulation, which consequently leads to TRIM24
upregulation in GC tumorigenesis.
In the present study, we further studied the biological
functions of miR-511 in GC cells and found that
ectopic expression of miR-511 inhibited cell growth,
colony formation ability and resulted in G0/G1 arrest
in GC cells, whereas miR-511 inhibition displayed oppos-
ing phenotypes. To further confirm whether TRIM24 is a
functional target of miR-511, we co-transfected miR-511
and TRIM24 and found that regulation of TRIM24 by
miR-511 relies on the TRIM24 3′UTR. More importantly,
our functional experiments revealed that restoration of
TRIM24 expression could attenuate the growth inhibition
caused by miR-511 overexpression in GC cells. This pro-
vided direct evidence that miR-511 inhibit GC cell prolif-
eration by suppressing TRIM24 expression. In addition, it
is worth noting that ectopic expression of TRIM24 did
not completely abrogate miR-511-induced effects, im-
plying that other downstream targets may be also in-
volved in miR-511 functions. Collectively, our data
present the new evidence to show that miR-511 serves
as a tumor suppressor in GC through negatively regulat-
ing TRIM24 expression. However, the molecular mecha-
nisms by which miR-511-TRIM24 promotes cell
proliferation still need to be further elucidated.
It is well-documented that PI3K/AKT and Wnt/β-
catenin pathways participate in a wide variety of cellular
process, such as cell growth, cell cycle, differentiation, and
tumorigenesis [42, 43]. Others and our data showed
TRIM24 was involved in activation of PI3K/AKT and
Wnt/β-catenin pathways [19, 44]. In this study, based on
the results that GC cell proliferation was affected by miR-
511 and TRIM24 expression, we studied whether PI3K/
AKTand Wnt/β-catenin pathways are also involved in this
process. Our results showed that miR-511 overexpression
significantly decreased the expression of p-Akt, β-catenin,
c-Myc and cyclinD1, suggesting that miR-511 acts as a
negative regulator of these two pathways. Previous study
also showed that miR-511 acts as a negative regulator of
PI3K/AKT pathway in liver cancer [38]. Further findings
showed overexpression of TRIM24 lacking its 3′-UTR
significantly restored PI3K/AKT and Wnt/β-catenin path-
ways in miR-511-transfected GC cells. Taken together,
these data imply that miR-511 suppresses PI3K/AKT and
Wnt/β-catenin pathways via targeting TRIM24, thus,
inactivation of PI3K/AKT and Wnt/β-catenin signaling
pathways are also involved in the anti-proliferative effects
of miR-511 in GC.
Conclusions
In conclusion, our study indicates that downregulation
of miR-511 accounts for the aberrant overexpression
of TRIM24 in GC tumorigenesis. MiR-511-mediated
suppression of TRIM24 inhibits cell proliferation
through PI3K/AKT and Wnt/β-catenin pathways. Our
characterization of this newly miR-511/TRIM24 axis
provide an improved understanding of the develop-
ment and progression of GC, and may provide new av-
enues for GC therapy.
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